News & Updates

Individuals with type 1 diabetes mellitus (T1DM) have a heightened risk of heart failure compared with those who have no diabetes, according to a study.

Current Food and Drug Administration (FDA)-approved intragastric balloon (IGB) systems, the gas-filled IGB (Obalon) and the fluid-filled IGB (Orbera), demonstrate similar effectiveness for the treatment of obesity, as shown in a recent study.

Researchers from the Chinese University of Hong Kong (CUHK) have discovered PDE1A rs10171703 as a novel genetic marker for coronary heart disease (CHD) in Chinese patients with type 2 diabetes mellitus (T2DM), indicating its potential utility for predicting CHD risk in this patient population.

Using alternative anthropometric measurements, a post hoc analysis that used data from the PARADIGM-HF* trial debunked the BMI-related ‘obesity paradox’ in a large cohort of patients with chronic heart failure with reduced ejection fraction (HFrEF).

Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.